A detailed history of E Fund Management Co., Ltd. transactions in Blueprint Medicines Corp stock. As of the latest transaction made, E Fund Management Co., Ltd. holds 7,508 shares of BPMC stock, worth $851,407. This represents 0.04% of its overall portfolio holdings.

Number of Shares
7,508
Previous 5,768 30.17%
Holding current value
$851,407
Previous $621,000 11.76%
% of portfolio
0.04%
Previous 0.03%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$84.1 - $120.5 $146,334 - $209,670
1,740 Added 30.17%
7,508 $694,000
Q2 2024

Aug 12, 2024

BUY
$85.18 - $108.78 $91,398 - $116,720
1,073 Added 22.85%
5,768 $621,000
Q1 2024

May 13, 2024

SELL
$73.17 - $99.79 $131,559 - $179,422
-1,798 Reduced 27.69%
4,695 $445,000
Q4 2023

Feb 06, 2024

SELL
$43.96 - $92.84 $91,085 - $192,364
-2,072 Reduced 24.19%
6,493 $598,000
Q3 2023

Nov 13, 2023

BUY
$46.9 - $66.0 $43,429 - $61,116
926 Added 12.12%
8,565 $430,000
Q2 2023

Aug 11, 2023

SELL
$42.2 - $66.37 $65,663 - $103,271
-1,556 Reduced 16.92%
7,639 $483,000
Q1 2023

May 11, 2023

BUY
$37.97 - $50.0 $10,137 - $13,350
267 Added 2.99%
9,195 $414,000
Q4 2022

Feb 14, 2023

BUY
$41.06 - $66.48 $109,465 - $177,235
2,666 Added 42.57%
8,928 $391,000
Q3 2022

Nov 14, 2022

SELL
$49.93 - $77.7 $142,150 - $221,211
-2,847 Reduced 31.25%
6,262 $413,000
Q2 2022

Aug 15, 2022

BUY
$45.23 - $70.15 $199,509 - $309,431
4,411 Added 93.89%
9,109 $460,000
Q1 2022

May 12, 2022

BUY
$54.1 - $110.08 $184,318 - $375,042
3,407 Added 263.9%
4,698 $300,000
Q1 2021

May 12, 2021

BUY
$90.71 - $108.28 $117,106 - $139,789
1,291 New
1,291 $125,000

Others Institutions Holding BPMC

About Blueprint Medicines Corp


  • Ticker BPMC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,719,600
  • Market Cap $6.77B
  • Description
  • Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...
More about BPMC
Track This Portfolio

Track E Fund Management Co., Ltd. Portfolio

Follow E Fund Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of E Fund Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on E Fund Management Co., Ltd. with notifications on news.